Drug Trial Radar · NCT05291689
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Apr 13, 2022
Primary completion
Oct 18, 2023
Study completion Feb 19, 2025
Sponsor
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Industry
- Sponsor type
- Industry
- First posted
- Mar 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)
Conditions
- Inflammatory Bowel Diseases
- Colitis, Ulcerative
Interventions
MORF-057Drug
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) ScoreTime frame: From baseline to 12 weeks
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Study Site
Tampa, Florida
Clinical Study Site
Lafayette, Louisiana
Clinical Study Site
Freehold, New Jersey
Clinical Study Site
Brooklyn, New York
Clinical Study Site
New York, New York
Clinical Study Site
Bydgoszcz, Poland
Clinical Study Site
Elblag, Poland
Clinical Study Site
Katowice, Poland
Clinical Study Site
Lodz, Poland
Clinical Study Site
Lodz, Poland
Clinical Study Site
Oświęcim, Poland
Clinical Study Site
Sopot, Poland
Clinical Study Site
Sosnowiec, Poland
Clinical Study Site
Staszów, Poland
Clinical Study Site
Tychy, Poland
Clinical Study Site
Warsaw, Poland
Clinical Study Site
Warsaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.